Compare Honeywell International Inc (HON) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell International Inc vs TG Therapeutics Inc — how do they compare? Honeywell International Inc trades at $207.73 (market cap $65.48B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Honeywell International Inc is far larger — about 8× TG Therapeutics Inc's market cap, and Honeywell International Inc pays a 1.36% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Honeywell International Inc for 91 Days and TG Therapeutics Inc for 16 Days on average.
| HON | TGTX | |
|---|---|---|
Market Cap | $65.48B | $8.16B |
Volume | 2,047,782 | 1,735,121 |
Sector | Industrials | Health |
52-Week High | $248.79 | $59.06 |
52-Week Low | $188.14 | $26.94 |
Typical Hold Time | 91 Days | 16 Days |
Enterprise Value | $90.27B | $8.37B |
Dividend Yield | 1.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $206.6, down 0.73% with bearish technical signals despite strong fundamental metrics including a low P/E of 7.94 and robust ROE of 47.43%. The company recently beat Q2 2026 EPS estimates and secured a $300 million refinery project, positioning for growth post-spinoff of its aerospace and advanced materials divisions. Analyst consensus remains strongly bullish with a $259.25 price target.
HON presents a compelling value opportunity with attractive valuation multiples and consistent earnings outperformance, though near-term technical weakness and increasing debt-to-asset ratios warrant caution. The company's strategic focus on automation and recent contract wins support long-term growth prospects despite cyclical industrial sector risks.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
